Developing products with
superior efficacy + reduced toxicities
against approved medicines in hematological malignancies
using a proprietary delivery platform.

Targeted transdermal delivery

Each product we work on is reimagined and studied to develop new dose regimens and define optimal targets. Our approach establishes new indications and delivers superior outcomes.

Careers

We are building a team dedicated to delivering breakthrough, transformative outcomes for patients with hematological malignancies. Learn more about career opportunities at Starton.

News and Events

07/28/20

Starton Therapeutics to Present at the LifeSci Partners Summer Symposium

NEW YORK, N.Y., July 28, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, announced today that Pedro Lichtinger,…

04/30/20

Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents

NEW YORK, N.Y., April 30, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced that it has…